Frontiers in Immunology (Jul 2022)
Characterization of the immune cell infiltration landscape in myxofibrosarcoma to aid immunotherapy
- Zi-Yue Zhao,
- Zi-Yue Zhao,
- Zhuo-Yuan Chen,
- Zhuo-Yuan Chen,
- Bin Yu,
- Bin Yu,
- Bo Xiao,
- Bo Xiao,
- Li-Yan Liu,
- Li-Yan Liu,
- Yu Xia,
- Yu Xia,
- Ao-Yu Li,
- Ao-Yu Li,
- Ping-Xiao Wang,
- Ping-Xiao Wang,
- Cheng Xiang,
- Cheng Xiang,
- Chao Liu,
- Chao Liu,
- Hui-Qin Yang,
- Hui-Qin Yang,
- Hui-Qin Yang,
- Hui Li,
- Hui Li,
- Tao Xiao,
- Tao Xiao
Affiliations
- Zi-Yue Zhao
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Zi-Yue Zhao
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- Zhuo-Yuan Chen
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Zhuo-Yuan Chen
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- Bin Yu
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Bin Yu
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- Bo Xiao
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Bo Xiao
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- Li-Yan Liu
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Li-Yan Liu
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- Yu Xia
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Yu Xia
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- Ao-Yu Li
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Ao-Yu Li
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- Ping-Xiao Wang
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Ping-Xiao Wang
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- Cheng Xiang
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Cheng Xiang
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- Chao Liu
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Chao Liu
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- Hui-Qin Yang
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Hui-Qin Yang
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- Hui-Qin Yang
- Department of Orthopedics, The Affiliated yanan Hospital of Kunming Medical University, Kunming, China
- Hui Li
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Hui Li
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- Tao Xiao
- Department of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China
- Tao Xiao
- Orthopedic Biomedical Materials Engineering Laboratory of Hunan Province, Changsha, China
- DOI
- https://doi.org/10.3389/fimmu.2022.916915
- Journal volume & issue
-
Vol. 13
Abstract
Myxofibrosarcoma (MFS) is a highly malignant subtype of soft tissue sarcoma, accounting for 5% of cases. Immunotherapy guided by immune cell infiltration (ICI) is reportedly a promising treatment strategy. Here, MFS samples (n = 104) from two independent databases were classified as ICI clusters A/B/C and gene clusters A/B/C. Then, a close relationship between ICI and gene clusters was established. We found that the features of these clusters were consistent with the characteristics of immune-inflamed tumors (cluster C), immune-desert tumors (cluster B), and immune-excluded tumors (cluster A). Moreover, cluster C was sensitive to immunotherapy. Finally, an independent ICI score was established to predict the therapeutic effect, which has prospects for application in guiding immunotherapy during clinical practice.
Keywords
